GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).
Epistemonikos ID: c107f58e5576c1bc61a1229313cc37280fa760b5
First added on: May 09, 2024